Metraipolis › archive › dc_13d65c7fcb06

Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia:… — Europe PMC PMID:41459484

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41459484
DOI
10.3389/fimmu.2025.1698710
License (as archived)
solo-consultazione
Archived
2026-11-07T17:45:52.566Z
SHA-256 of the archived text
06246c7be7bcbfeb430c91b9e06b2c2ad0697d46fa0511ec02e6ab8009d7b036
Stable URL of this page
https://metraipolis.com/documento/dc_13d65c7fcb06

How to cite

Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia:… — Europe PMC PMID:41459484 — Europe PMC (en), https://europepmc.org/article/MED/41459484 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_13d65c7fcb06 (Metraipolis archive dc_13d65c7fcb06, sha256 06246c7be7bcbfeb430c91b9e06b2c2ad0697d46fa0511ec02e6ab8009d7b036)
BibTeX
@misc{dc13d65c7fcb06,
  title = {Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia:… — Europe PMC PMID:41459484},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41459484},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_13d65c7fcb06; sha256 06246c7be7bcbfeb430c91b9e06b2c2ad0697d46fa0511ec02e6ab8009d7b036},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41459484. Agents can read the archived copy with the MCP tool read_document.